Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Metatranscriptomic

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT05388968CompletedPrimary

Metatranscriptomic Next Generation Sequencing in First Trimester Trophoblast With Increased Fetal Nuchal Translucency (METAHCN)

Showing all 1 trials

Research Network

Common Treatments

  • Metatranscriptomic1
  • Specific Microbiologic Diagnosis1

Active Sponsors

  • URC-CIC Paris Descartes Necker Cochin1
  • Pathogen Discovery Laboratory1
  • Institut Pasteur1
  • Assistance Publique - Hôpitaux de Paris1

Top Investigators

Activity Timeline